Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 5, 2016BMC MedicineOpen Access

Cancer immunotherapy: the beginning of the end of cancer?

View Full Paper
Ask AI
Bookmark
Share

Authors

SFSofia FarkonaUniversity Health Network
Eleftherios P. Diamandis
Eleftherios P. DiamandisMount Sinai HospitalIBIvan M. BlasutigUniversity of Ottawa

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Farkona et al. (2016) studied this question.

synapsesocial.com/papers/69de970482d632c6bbe9395fhttps://doi.org/10.1186/s12916-016-0623-5
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The role of CD4+ T cell responses in antitumor immunity1998 · 681 citations
  2. 2Epitope Landscape in Breast and Colorectal Cancer2008 · 421 citations
  3. 3Towards patient‐specific tumor antigen selection for vaccination2002 · 82 citations
  4. 4Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).2014 · 233 citations